GILD vs INSM
GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments. INSM: Insmed is a biopharmaceutical company dedicated to transforming the lives of patients suffering from serious and rare respiratory and inflammatory diseases.
Side-by-side fundamentals
| Metric | GILD | INSM | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $130.86 | $132.55 | |
| Market cap as of 2026-08-08 | $162.5B | $28.7B | |
| P/E as of 2026-08-08 | 19.49 | n/a | |
| PEG as of 2026-08-08 | 2.53 | n/a | |
| Net margin as of 2026-08-08 | -10.6% | -144.4% | GILD higher |
| Gross margin as of 2026-08-08 | +81.5% | +81.8% | INSM higher |
| Operating margin as of 2026-08-08 | -8.2% | -140.6% | GILD higher |
| ROE as of 2026-08-08 | -16.3% | -130.1% | GILD higher |
| ROA as of 2026-08-08 | -5.8% | -51.6% | GILD higher |
| Debt / equity as of 2026-08-08 | 0.94 | 1.03 | GILD lower |
| Revenue growth (YoY) as of 2026-08-08 | +5.5% | +115.1% | INSM higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | +35.2% | INSM higher |
| Dividend yield as of 2026-08-08 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-08 | 0.33 | 0.86 | |
| 1-year return as of 2026-08-06 close | +18.7% | +19.1% | INSM higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.